Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist
Open Access
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 525, 67-75
Abstract
No abstract availableKeywords
Funding Information
- China Scholarship Council
- Rijksuniversiteit Groningen (T3-112)
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación
- Stichting voor de Technische Wetenschappen (11056)
This publication has 41 references indexed in Scilit:
- Resistance to TRAIL in non-transformed cells is due to multiple redundant pathwaysCell Death & Disease, 2013
- Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian CancerJournal of Drug Delivery, 2013
- Granule exocytosis mediates immune surveillance of senescent cellsOncogene, 2012
- Therapy-Induced Senescence in CancerJNCI: Journal of the National Cancer Institute, 2010
- High Levels of Id1 Expression Define B1 Type Adult Neural Stem CellsCell Stem Cell, 2009
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor SuppressorPLOS Biology, 2008
- TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotypeBreast Cancer Research and Treatment, 2008
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007
- Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptorProceedings of the National Academy of Sciences, 2006
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999